CD274 and neoplasm: Although anoikis sensitization is not a primary mode of action of Atezolizumab, the capability of EMT suppression of Atezolizumab and the overexpression of PD-L1 on circulating tumor cells [54] strongly suggest the anoikis-sensitizing effect of anti-PD-L1 antibody.